Business Wire

Mary Kay Inc. Caps Off Landmark Scientific Credentialing Year at 73rd Society of Cosmetic Chemists Meeting

20.12.2019 17:00:00 EET | Business Wire | Press release

Share

In 2019, Mary Kay Inc. continued its decades-long commitment to skin science research by revealing the results of multiple groundbreaking studies and fostering academic discussion with industry peers at scientific symposiums around the globe. Most recently, Mary Kay was in New York City for the 73rd Society of Cosmetic Chemists Meeting, where the brand sponsored, collaborated, and explored applications of skin microbiome with leading experts in the field.

“New research suggests that microbes play an important role in overall skin health, and as leading skincare innovators, Mary Kay is heavily invested in further exploration of their impact,” said Dr. Lucy Gildea, Chief Scientific Officer at Mary Kay. “We have a commitment to take an active role in the beauty and scientific communities through participation in global dermatological conferences like the Society of Cosmetic Chemists Meeting, where we can share and learn from other scientific experts to help us develop more effective products.”

The Society of Cosmetic Chemists Meeting convenes over 1,300 attendees from some of the top cosmetic and personal care brands and manufacturers. Participants are encouraged to engage with speakers presenting the latest research and innovations of interest to cosmetic scientists, exchange ideas with peers, and reconnect with colleagues from around the globe.

Mary Kay sponsored the educational session at the meeting, including topics Quorum Quenching: the New Way to Keep Microbiome Under Control, Exploring New Applications in Personal Care: Balancing our Skin Microbiota, Global Microbiome Effects, and Temporal Variation of the Facial Skin Microbiome.

Additional 2019 Scientific Research and Credentialing

The 73rd Society of Chemists Meeting is the latest event in a series of Mary Kay presentations with the scientific and academic communities that reinforce the brand’s longstanding commitment to advancing skin health research and development. Every year, Mary Kay conducts hundreds of thousands of scientific tests on products and ingredients to ensure the highest standards of safety, quality and performance. Mary Kay holds more than 1,500 patents for products, technologies and packaging designs in its global portfolio. Recently, the company announced the opening of a more than $100 million state-of-the-art manufacturing and R&D facility in Lewisville, Texas.

In 2019, Mary Kay focused on three pillars in its commitment to skin health, including pollution; skin barrier health and sensitive skin; and the understanding of skin aging and strategies to intervene:

Pollution and Skin Health

  • May: Mary Kay sponsored an exclusive symposium on the impact of pollution on skin health in the Latin America region at the prestigious Reunión Anual de Dermatólogos Latinoamericanos (RADLA) in Buenos Aires, Argentina. Dr. Gildea moderated this symposium with 3 expert Brazilian dermatologists sharing research on the impact of air pollution on skin. It was concluded that antioxidants would be a viable way to counteract the negative effects of pollution on skin. Fortunately, Mary Kay also presented findings on an antioxidant complex that can help delay the premature signs of aging related to the damaging effects of air pollution.
  • June: Mary Kay the 24th World Congress of Dermatology in Milan, Italy. Mary Kay sponsored a Questions and Answers session with 2 dermatology experts on the impact of environmental stressors in Europe on skin. Dr. Michelle Hines, Global Upstream Research & Technology at Mary Kay hosted this event featuring two renowned Europe skin experts:
    • Jean Krutmann, M.D., Professor & Director at Leibniz Research Institute for Environmental Medicine – Dusseldorf, Germany.
    • Stefanie Williams, M.D., Dermatologist & Medical Director at EUDELO – London, United Kingdom.
  • June: At the 5th Future of Formulations in Cosmetics Summit in Dusseldorf, Germany, Dr. Hines revealed Mary Kay’s ongoing research on an antioxidant complex that helps delay the onset of premature signs of aging related to the damaging effects of diesel exhaust particles (DEP) on skin cells. The breakthrough technology, found in the Mary Kay® TimeWise® Miracle Set 3D skin care line, provides a powerful free-radical fighting regimen with an exclusive, patent-pending, three-dimensional approach to skin aging.

Skin Barrier Health and Sensitive Skin

  • March: At the 20th World Dermatology Congress in Singapore, David Gan, Senior Principal Scientist at Mary Kay Inc., presented some new insights in evaluating and understanding facial redness. Based on this work, Mary Kay scientists identified skincare technology that helps reduce the production of pro-inflammatory proteins and enzymes in the skin and developed a cosmetic formulation containing these ingredients to effectively address facial redness using unique clinical measures.
  • August: Mary Kay China’s Sr. Manager for Medical Affairs, Dr. Jenny Jiang, shared some strategies from Mary Kay research to improve the skin barrier function and facial redness at the Annual Meeting of the Dermatology Committee organized by the Chinese Association of Integrative Medicine in Lanzhou, Gansu Province, China. These findings may provide important insights to understanding sensitive skin.
  • November: Mary Kay was a symposium sponsor at the 44th annual meeting of The Japanese Society of Investigative Dermatology (JSID) in Aomori, Japan. Dr. Gildea moderated an educational symposium exploring environmental protection strategies against skin aging in Asians, protein response to skin inflammation and skin barrier defects. The panel featured three renowned dermatologists:
    • Dr. Akimichi Morita, MD Ph.D., Department of Geriatric and Environmental Dermatology at Nagoya City University Graduate School of Medical Sciences
    • Dr. Sang Eun Lee, MD Ph.D., Department of Dermatology, Gangnam Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine in Seoul, Korea
    • Dr. Gyohei Egawa, MD Ph.D., Department of Dermatology, Kyoto University Graduate School of Medicine

Understanding of Skin Aging and Skin Health and Strategies to Intervene

  • March: At the Skin of Color Society Symposium in Washington. D.C., Dr. Shoná Burkes-Henderson, Associate Principal Scientist, Clinical Research, revealed new research on navy bean extract and its ability to regulate melanogenesis, leading to an improvement in uneven skin tone and facial hyperpigmentation. Dr. Burkes-Henderson also presented a new approach to help improve facial erythema, or redness, at the American Academy of Dermatology Annual Meeting.
  • May: Mary Kay Associate Principal Scientist Dr. Tiffany Carle attended 77th Annual Meeting of the Society for Investigative Dermatology in Chicago, where she presented new data from analyzing the effects of a serum containing five botanical fruit extracts known to be rich in vitamin C on skin appearance. As part of this study, Mary Kay researchers treated artificial skin tissue with this serum and utilized a genomic approach to understand how the serum affected the skin.
  • June: Mary Kay sponsored the University of the Philippines Medical Alumni Society of America (UPMASA) 34th Annual Grand Convention (AGC) in Dallas. The conference convened more than 500 doctors from the U.S. and the Philippines to discuss topics ranging from dermatology to orthopedics and neurology.
  • September: Mary Kay shared its latest research targeting the causes and underlying mechanisms of slackened skin at the 49th Annual Meeting of the European Society for Dermatological Research (ESDR) held in Bordeaux, France. Dr. Michelle Hines shared data on technology that targeted slackened skin leading to improvement in skin clinical measures.
  • September: Mary Kay presented findings on research experiments that demonstrated how sunscreen viscosity, a property that effects application to skin, can be adjusted using processing parameters at the 2019 Sunscreen Symposium presented by the Florida chapter of the Society of Cosmetic Chemists in Lake Buena Vista, Florida.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release

Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila

PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye